Celyad Oncology SA Announces Capital Increase and Update on Total Number of Voting Rights and Shares

Celyad Oncology SA has increased its share capital to EUR 9,216,154.53 and is now represented by 44,761,905 shares. The company has issued 3,333,333 new shares to an affiliate of Fortress Investment Group. The total number of voting rights is 53,630,280, and the total number of diluted shares is 48,618,039.

Title: Celyad Oncology SA Increases Share Capital and Total Number of Shares

Mont-Saint-Guibert, Belgium — Celyad Oncology SA (Euronext: CYAD) has announced a significant increase in its share capital and total number of shares, following the issuance of 3,333,333 new shares to an affiliate of Fortress Investment Group. The company's share capital has been augmented to EUR 9,216,154.53, represented by 44,761,905 shares [1].

The new shares have increased the total number of shares with single voting rights to 35,893,530 and the total number of shares with double voting rights to 8,868,375. Consequently, the total number of voting rights has risen to 53,630,280. Additionally, the total number of diluted shares, including attributed warrants, stands at 48,618,039 [1].

This capital increase aligns with Celyad Oncology's strategic business model, which includes the development of its proprietary CAR-T technology platforms and intellectual property. The company's forward-looking statements highlight potential benefits from its updated strategic business model, including associated transactions and partnerships, and statements regarding the potential value of its IP assets [1].

The announcement follows the issuance of 3,333,333 new shares, which has increased the total number of shares and voting rights. This move signifies Celyad Oncology's commitment to growth and its ability to attract investment from prominent entities like Fortress Investment Group. The company's strategic focus on its CAR-T technology platforms and intellectual property underscores its commitment to innovation and the development of cutting-edge biotechnology solutions [1].

For further information, investors are encouraged to contact Matthew Kane, Chief Executive Officer (CEO), at investors@celyad.com.

References:
[1] https://www.stocktitan.net/news/CYAD/celyad-oncology-sa-information-on-the-total-number-of-voting-rights-5aovj2bu5ws8.html
[2] https://www.nasdaq.com/articles/cipher-mining-cifr-q2-eps-surges